YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
MoonLake Immunotherapeutics (MLTX) could receive US Food and Drug Administration approval for sonelo PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
[Macro closeup of red swollen boil pimple on leg skin of female woman showing medical condition called hidradenitis suppurativa] krblokhin * MoonLake Immunotherapeutics (MLTX [https://seekingalpha.com/symbol/MLTX]) submitted a BLA to the U…
DelveInsight Business Research LLP The launch of emerging therapies such as ILUMYA/ILUMETRI (tildrakizumab-asmn; Sun Pharma), Izokibep (Affibody Medical), ICOTYDE (icotrokinra; Johnson & Johnson), Zasocitinib (TAK-279; Takeda), Sonelokimab…
Shares of MoonLake Immunotherapeutics (MLTX) have gained 0.2% over the past four weeks to close the last trading session at $18.99, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analys…
Shares of MoonLake Immunotherapeutics (MLTX) have gained 0.2% over the past four weeks to close the last trading session at $18.99, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analys…
Key Points The executive sold 39,120 shares on June 22. The sale represented 3.4% of Bodenstedt's direct holdings. Bodenstedt retains 1,115,435 Class A ordinary shares.10 stocks we like better than MoonLake Immunotherapeutics › CFO Sells 3…
CFO Sells 39,120 MoonLake Immunotherapeutics Shares Worth ~$862,000 On June 22, Matthias Bodenstedt, Chief Financial Officer of MoonLake Immunotherapeutics (NASDAQ:MLTX), sold 39,120 common shares in an open-market transaction valued at ap…
We recently compiled a list of the 10 Best Biotech Stocks to Buy According to Analysts. MoonLake Immunotherapeutics (NASDAQ:MLTX) is one of the best biotech stocks on this list. TheFly reported on June 22 that Clear Street maintained its B…
MoonLake Immunotherapeutics recently reported past Week 52 Phase 3 VELA data showing strong efficacy and a consistent safety profile for sonelokimab in moderate-to-severe hidradenitis suppurativa, including adults and adolescents, and foll…
MoonLake Immunotherapeutics (NASDAQ: MLTX) clearly wasn't immune to negative investor sentiment on Wednesday. The clinical-stage biotech's equity slumped by almost 6% during that trading session, mainly due to a secondary share issue annou…
Key Points It aims to raise up to $200 million in the offering. This will support its efforts to bring its top drug candidate to market.10 stocks we like better than MoonLake Immunotherapeutics › MoonLake Immunotherapeutics(NASDAQ: MLTX) c…
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.4%, and the actively tra PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
* MoonLake Immunotherapeutics (MLTX [https://seekingalpha.com/symbol/MLTX]) said it has priced an underwritten public offering of 9M Class A ordinary shares at $20.00 per share, along with pre-funded warrants to purchase up to 1M additiona…
(RTTNews) - MoonLake Immunotherapeutics (MLTX) has priced an upsized $200 million public offering as the company moves to accelerate development and potential commercialization activities for its lead inflammatory disease candidate, Sonelo…
MoonLake Immunotherapeutics AG ZUG, Switzerland, June 23, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) ("MoonLake"), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joint disea…
ZUG, Switzerland, June 23, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joint diseases, today announced the pricin…
[Financial chart with moving up arrow graph in stock market on blue color background] Wall Street finished Monday’s session in mixed fashion as renewed uncertainty around weekend U.S.–Iran peace negotiations pressured sentiment, while weak…
ZUG, Switzerland, June 22, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joint diseases, today announced a proposed…
MoonLake Immunotherapeutics AG ZUG, Switzerland, June 22, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) ("MoonLake"), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joint disea…
(RTTNews) - Biotech companies are seeing significant pre-market activity this Monday. Pre-market movers give traders an early read on momentum, sentiment, and potential volatility for the trading day. Price swings before the opening bell t…
(RTTNews) - MoonLake Immunotherapeutics (MLTX), a clinical-stage biotechnology company, on Monday announced positive 52 week results from the Phase 3 registrational VELA-1 and VELA-2 clinical trials evaluating Sonelokimab in patients with…
ojos de hojalata/iStock via Getty Images MoonLake Immunotherapeutics (MLTX [https://seekingalpha.com/symbol/MLTX]) on Sunday said its experimental drug sonelokimab delivered strong one-year results in two Phase 3 trials for hidradenitis su…
MoonLake Immunotherapeutics AG Results from the Phase 3 VELA clinical trials at Week 52 in adults with moderate-to-severe hidradenitis suppurativa (HS) demonstrate sonelokimab's (SLK) potential best-in-class and best-in-disease profile, wi…
Results from the Phase 3 VELA clinical trials at Week 52 in adults with moderate-to-severe hidradenitis suppurativa (HS) demonstrate sonelokimab’s (SLK) potential best-in-class and best-in-disease profile, with consistent responses that ar…
Key Points Bodenstedt sold 13,653 shares for a transaction value of ~$273,000 at around $20.02 per share on May 11, 2026. The sale represented 1.1% of his direct holdings, reducing his direct position from 1,186,084 to 1,172,431 shares. Th…
On May 11, 2026, MoonLake Immunotherapeutics(NASDAQ:MLTX) Chief Financial Officer Matthias Bodenstedt reported the sale of 13,653 common shares in an open-market transaction, according to the SEC Form 4 filing. Transaction summary Metric V…
We recently compiled a list of the 8 Best Immunology Stocks to Buy According to Hedge Funds. MoonLake Immunotherapeutics (NASDAQ:MLTX) is among the best immunology stocks. TheFly reported on May 11 that H.C. Wainwright increased its price…
MoonLake Immunotherapeutics reported a first‑quarter 2026 net loss of US$69.71 million, while securing alignment with the U.S. FDA on a planned September 2026 Biologics License Application for sonelokimab in hidradenitis suppurativa, inclu…
Shares of MoonLake Immunotherapeutics bounded higher Monday after the biotech said it met with the Food and Drug Administration in April. Continue Reading
medical research 17 ©This Is Engineering MoonLake Immunotherapeutics (NASDAQ:MLTX) shares rose more than 4% in premarket trading on Monday after the biotechnology company announced positive progress in discussions with the U.S. Food and Dr…
(Updates to include details on MoonLake Immunotherapeutics's meeting with the FDA in the last two pa PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
* MoonLake Immunotherapeutics press release [https://seekingalpha.com/pr/20508432-moonlake-immunotherapeutics-announces-positive-outcome-from-its-final-pre-bla-meeting-with] (MLTX [https://seekingalpha.com/symbol/MLTX]): Q1 GAAP EPS of -$0…
MoonLake Immunotherapeutics AG MoonLake conducted a positive final pre-BLA (Biologics License Application) meeting with the U.S. Food and Drug Administration (FDA), where MoonLake and the FDA aligned on submission plans and the label strat…
MoonLake conducted a positive final pre-BLA (Biologics License Application) meeting with the U.S. Food and Drug Administration (FDA), where MoonLake and the FDA aligned on submission plans and the label strategy for sonelokimab (SLK) in hi…
Key Points CEO Jorge Santos da Silva sold 150,000 shares for a transaction value of approximately ~$2.75 million, based on a weighted average sale price of $18.35 per share. The sale represented 4.9% of Mr. Santos da Silva’s direct holding…
Chief Executive Officer Jorge Santos da Silva reported the sale of 150,000 shares of MoonLake Immunotherapeutics(NASDAQ:MLTX) through multiple open-market transactions on April 10, 2026 and April 13, 2026, according to a SEC Form 4 filing.…